Similar to BTZ and CFZ25, 27, b-AP15 effectively increased cell surface DR5 levels and enhanced apoptosis induced by both TRAIL and AMG655, a DR5 agonistic antibody, in different cancer cell lines in a DR5-dependent manner, as evidenced by DR5 deficiency fully protecting cancer cells from undergoing apoptosis when treated with b-AP15 in combination with either TRAIL or AMG655 (Fig. 5). The gene discussed is CASC3; the disease is cancer.